Article
Pathology
Heng Zhang, Junling Jian, Hai Chen, Xiaodong Zhu, Jianfeng Xie, Xianquan Xu
Summary: The expression level of LAGE3 in NSCLC is associated with worse overall survival. LAGE3 can promote NSCLC development by activating the AKT/PI3K signaling pathway, leading to accelerated metastasis and increased cell stemness, as demonstrated by cell and animal experiments.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Biochemistry & Molecular Biology
Huan Ma, Siyu Jiang, Yinan Yuan, Ji Li, Yizhuo Li, Yanping Lv, Tengjiao Du, Jingqian Guan, Xizi Jiang, Lei Tian, Qianqian Zheng, Lianhe Yang, Qingchang Li
Summary: RUNX1, a member of the RUNX family, is involved in the regulation of non-small cell lung cancer. It promotes cell proliferation and migration via the mTOR pathway and may serve as a potential therapeutic target for NSCLC.
Article
Biotechnology & Applied Microbiology
Siou-Min Luo, Wen-Chivan Tsai, Chia-Kuang Tsai, Ying Chen, Dueng-Yuan Hueng
Summary: The study showed higher expression of ARID4B in WHO grade IV tumors, and knocking down ARID4B suppressed glioma cell proliferation and induced apoptosis, indicating that ARID4B may act as an oncogene in human gliomas.
ONCOTARGETS AND THERAPY
(2021)
Article
Medicine, Research & Experimental
Xiaofeng Yu, Ying Li, Guodong Jiang, Jian Fang, Zhaolei You, Guangyuan Shao, Zheng Zhang, Aihong Jiao, Xiaonu Peng
Summary: This study revealed that FGF21 is upregulated in lung cancer and can promote cell growth and migration by activating the SIRT1/PI3K/AKT signaling pathway, indicating FGF21 as a potential therapeutic target for lung cancer treatment.
Article
Biochemistry & Molecular Biology
Xuefeng Li, Cheng Li, Chenchen Guo, Qiqi Zhao, Jiayu Cao, Hsin-Yi Huang, Meiting Yue, Yun Xue, Yujuan Jin, Liang Hu, Hongbin Ji
Summary: The heterogeneity of SCLC phenotype is associated with different sensitivity to chemotherapy; activation of the PI3K/Akt/mTOR pathway promotes phenotypic transition and chemo-resistance in SCLC cells; combining chemotherapy with PI3K/Akt/mTOR pathway inhibitors can overcome chemo-resistance in SCLC treatment.
JOURNAL OF GENETICS AND GENOMICS
(2021)
Article
Medicine, Research & Experimental
Minglei Song, Nan Zhang, Fumin Cao, Junfeng Liu
Summary: PKNOX2 has been identified as a tumor suppressor in lung cancer by inhibiting the PI3K/AKT/mTOR signaling pathway.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Cell Biology
Xiaoyu Yi, Chao Zhang, Baojie Liu, Guojun Gao, Yaqi Tang, Yongzheng Lu, Zhifang Pan, Guohui Wang, Weiguo Feng
Summary: This study identified the role of RPL22L1 in the progression of prostate cancer (PCa). It was found that the expression of RPL22L1 was significantly higher in PCa tissues compared to normal prostate tissues, and it promoted the proliferation and invasion of PCa cells by activating the PI3K/Akt/mTOR pathway.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Zhongnan Wu, Wen Li, Qing Tang, Laiqiang Huang, Zhaochun Zhan, Yaolan Li, Guocai Wang, Xiaoyong Dai, Yubo Zhang
Summary: PEG, derived from fungi, can inhibit the growth of NSCLC cells by suppressing cell cycle and MET pathway. The study suggests that PEG has the potential to be developed as a drug candidate for treating NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Jiming Du, Aimin Gong, Xuefeng Zhao, Guixin Wang
Summary: The study demonstrates that overexpression of PUS7 in colorectal cancer increases cell proliferation and invasion, inhibits cell apoptosis, primarily through activating the PI3K/AKT/mTOR signaling pathway.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Medicine, Research & Experimental
Tianshui Sun, Fangfang Bi, Zhuonan Liu, Qing Yang
Summary: In ovarian cancer patients, TMEM119 is overexpressed and associated with poor survival. Experimental results indicate TMEM119 promotes proliferation, invasion, and migration of ovarian cancer cells. Additionally, TMEM119 may exert oncogenic effects by regulating PDGFRB expression and activating the PI3K/AKT signaling pathway.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Shike Yan, Bing Zhang, Jingwen Feng, Haigang Wu, Namin Duan, Yamin Zhu, Yueliang Zhao, Shuang Shen, Kai Zhang, Wenhui Wu, Ning Liu
Summary: FGFC1 selectively suppressed the growth of NSCLC cells with EGFR mutation, induced apoptosis of erlotinib-resistant NSCLC cells via mitochondrial dysfunction and ROS accumulation, and inhibited EGFR and its downstream PI3K/Akt/mTOR pathway by directly binding to EGFR. Additionally, FGFC1 inhibited the migration and invasion of NSCLC cells and effectively inhibited tumor growth in a xenograft model, indicating its potential as a candidate for erlotinib-resistant NSCLC therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Biantiao Xu, Mingyue Guo, Li Ma, Ammad Ahmad Farooqi, Linlin Wang, Gan Qiao, Minghua Liu, Ling Zuo, Hanlin Ye, Xiukun Lin, Shousong Cao
Summary: Mere15, extracted from the marine species Meretrix meretrix, is a 15 kDa anticancer polypeptide that displays potent antitumor activity by inhibiting the PI3K/Akt/mTOR signaling pathway. It significantly inhibits the growth, invasion, and migration of non-small cell lung cancer cells and has the potential to be developed as a novel antimetastatic agent for NSCLC treatment.
Article
Oncology
Jinping Wang, Xue Luo, Jinxi Lu, Yuan Miao, Qingchang Li, Liang Wang
Summary: Rab22a promotes malignant phenotypes of lung adenocarcinoma by upregulating the PI3K/Akt/mTOR signaling pathway and interacts with PI3Kp85 alpha. It may serve as a potential therapeutic target for lung adenocarcinoma.
EXPERIMENTAL CELL RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Hong Li, Jing Lin, Fei Yang, Junzhu Deng, Jia Lai, Jing Zeng, Wenjun Zou, Nan Jiang, Qianqian Huang, Hua Li, Jian Liu, Mao Li, Zhirong Zhong, Jianming Wu
Summary: This study investigated the mechanism of action of Sanguisorba officinalis L. (SOL) in non-small cell lung cancer (NSCLC) using network pharmacology. In vitro and in vivo experiments confirmed that SOL effectively inhibited the proliferation, migration, and invasion of NSCLC cells. The suppression of NSCLC by SOL was achieved through downregulation of the PI3K/AKT/mTOR signaling pathway.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Shuyan Han, Zhihua Tian, Huifang Tian, Haibo Han, Jun Zhao, Yanna Jiao, Chunli Wang, Huifeng Hao, Shan Wang, Jialei Fu, Dong Xue, Hong Sun, Pingping Li
Summary: This study examined the role of hepatoma-derived growth factor (HDGF) in gefitinib resistance in non-small cell lung cancer (NSCLC) and identified the underlying mechanisms. The results showed that HDGF overexpression aggravated the malignant phenotype of NSCLC cells, while HDGF knockdown reversed these effects. The overexpression of HDGF also led to gefitinib resistance, while knockdown enhanced gefitinib sensitivity. Higher levels of HDGF in plasma or tumor tissue were associated with gefitinib resistance. HDGF activated the Akt and ERK signaling pathways, independent of EGFR phosphorylation, contributing to gefitinib resistance.
CELL DEATH DISCOVERY
(2023)